Avantor (NYSE:AVTR) Price Target Raised to $26.00 at Barclays

Avantor (NYSE:AVTR) had its price target raised by Barclays from $25.00 to $26.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price target would suggest a potential upside of 17.20% from the stock’s current price.

A number of other research firms have also weighed in on AVTR. Raymond James dropped their target price on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. Wells Fargo & Company reduced their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. UBS Group reiterated a “neutral” rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Finally, Robert W. Baird reduced their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.46.

Avantor Stock Down 0.4 %

Shares of NYSE:AVTR traded down $0.10 during midday trading on Monday, hitting $22.19. 2,279,693 shares of the company’s stock were exchanged, compared to its average volume of 4,626,846. Avantor has a 12 month low of $19.59 and a 12 month high of $28.00. The company has a market cap of $15.10 billion, a PE ratio of 48.11, a price-to-earnings-growth ratio of 3.97 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The stock has a 50 day moving average price of $21.69 and a 200-day moving average price of $23.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AVTR. First Bank & Trust grew its holdings in Avantor by 6.3% during the 4th quarter. First Bank & Trust now owns 18,899 shares of the company’s stock valued at $398,000 after buying an additional 1,117 shares in the last quarter. Global Retirement Partners LLC grew its stake in Avantor by 76.7% during the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after acquiring an additional 1,067 shares in the last quarter. Peregrine Capital Management LLC increased its holdings in Avantor by 20.7% during the 4th quarter. Peregrine Capital Management LLC now owns 857,538 shares of the company’s stock worth $18,068,000 after acquiring an additional 147,202 shares during the period. Venturi Wealth Management LLC lifted its stake in Avantor by 504.8% in the 4th quarter. Venturi Wealth Management LLC now owns 7,572 shares of the company’s stock worth $160,000 after purchasing an additional 6,320 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its holdings in Avantor by 13.8% in the 4th quarter. CIBC Asset Management Inc now owns 27,507 shares of the company’s stock valued at $580,000 after purchasing an additional 3,342 shares during the period. 95.08% of the stock is owned by institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.